Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using TCR alpha/beta/CD19-depleted Allogeneic Hematopoietic Progenitor Cells

Review the clinical trials studying tcr alpha/beta/cd19-depleted allogeneic hematopoietic progenitor cells on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-6 of 6

Donor Stem Cell Transplant after TCR Alpha-Beta+ T Cells/CD19+ B Cell Depletion for the Treatment of Children and Young Adults with Malignant or Non-malignant Hematological Disorders
Status: Active
Location: 2 locations
Specialized Stem Cell Transplant Product (Hematopoietic Progenitor Blood Cell Graft Cells) for the Treatment of Children, Adolescent and Young Adult Patients with Hematologic Cancers
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
αβT Cell/CD19+ B Cell Depletion for Alternative Donor Stem Cell Transplant for Children and Young Adults with Hematologic Malignancies
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Modified Memory-Like NK Cells and TCRαβ T-cell Depleted Half-Matched Related Donor Transplant for the Treatment of High-Risk Acute Myeloid Leukemia (ABCD NK trial)
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Donor Blood Stem Cells (Ex Vivo TCR Alpha/Beta and CD19-Depleted Stem Cells) for the Prevention of Graft-versus-Host Disease in Pediatric Patients with Blood Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
CD45RA Depleted Peripheral Stem Cell Addback to Prevent Graft versus Host Disease and Infection after Alternative Donor TCRalpha beta/CD19 Depleted Hematopoietic Stem Cell Transplant
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania